Tag: BIO PHA HEA MTC

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and...

Made Scientific and Sentinel BioTherapeutics Announce Strategic Manufacturing Partnership to Advance Ph I/II Allogeneic ePP Encapsulated Cell Therapy Program

PRINCETON, N.J. and HOUSTON, July 15, 2025 /PRNewswire/ -- Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Sentinel...

- A word from our sponsors -

HomeTagsBIO PHA HEA MTC

Folding IBC Market to Reach USD 5.2 Billion by 2035 as Returnable Packaging Solutions and Logistics Optimization Drive Global Demand

AMERICA HAS SPOKEN: BEGGIN’ UNVEILS THE BEGGIN’ XI TOP DOG

Cognision Publishes Landmark Study Showing Ketamine Produces Opposite Brain Effects in Different Patients — and That Outcome Can Be Predicted Using EEG

Tag: BIO PHA HEA MTC

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

Made Scientific and Sentinel BioTherapeutics Announce Strategic Manufacturing Partnership to Advance Ph I/II Allogeneic ePP Encapsulated Cell Therapy Program

Explore

Press Releases

News & Opinion

Living

Others

Follow us